Diseases [C] » Immune System Diseases [C20] » Graft vs Host Disease
Description
The clinical entity characterized by anorexia, diarrhea, loss of hair, leukopenia, thrombocytopenia, growth retardation, and eventual death brought about by the GRAFT VS HOST REACTION. MeSH
Hierarchy View
Subtype Terms (1)
Bronchiolitis Obliterans Syndrome
1 approved drug
Phase 4 Indicated Drugs (20)
Phase 2 Indicated Drugs (112)
allogeneic mesenchymal stem cells
allogeneic natural killer cells
autologous expanded mesenchymal stem cells oti-010
autologous umbilical cord blood
lymphocyte immune globulin, anti-thymocyte globulin (equine) (Atgam)
Other Experimental Indicated Drugs (14)
Organization Involved with Phase 4 Indications (19)
Organization Involved with Phase 3 Indications (70)
Albert Einstein Israelite Hospital
Assistance Publique - Hôpitaux de Paris
Blood and Marrow Transplant Clinical Trials Network
Center for International Blood and Marrow Transplant Research
Centre National de Greffe de Moelle Osseuse
Chinese Academy of Medical Sciences
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Federal University of Rio de Janeiro
Grupo de Estudos Multicentricos em Onco-Hematologia
National Cancer Institute (NCI)
National Heart, Lung, and Blood Institute (NHLBI)
National Institutes of Health (NIH)
Organization Involved with Phase 2 Indications (177)
Andalusian Initiative for Advanced Therapies
Associazione Italiana per la Ricerca sul Cancro
Bambino Gesù Hospital and Research Institute
Cambium Medical Technologies LLC
Case Western Reserve University
Cell Therapy Transplant Canada
Christian Medical College, Vellore, India
City of Hope National Medical Center
Clinica Universidad de Navarra
Etablissement Français du Sang
Generon (Shanghai) Corporation Ltd.
Gesellschaft fur Medizinische Innovation – Hamatologie und Onkologie mbH
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
Grupo Espanol de trasplantes hematopoyeticos y terapia celular
Hackensack University Medical Center
Icahn School of Medicine at Mount Sinai
Innovent Biologics (Suzhou) Co. Ltd.
Instituto de Medicina Molecular
instituto Portugues de Oncologia Porto
Jolimont Hospital Haine Saint Paul
Memorial Sloan-Kettering Cancer Center
Michigan Cornea Consultants, PC
National Center for Advancing Translational Science (NCATS)
National Institute of Allergy and Infectious Diseases (NIAID)
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Norwegian University of Science and Technology
Oregon Health and Science University
Pavlov First Saint Petersburg State Medical University
Russian Academy of Medical Sciences
Sickle Cell Transplant Advocacy & Research Alliance (STAR)
State University of New York, Buffalo
The Korean Society of Hematopoietic Stem Cell Transplantation
The Leukemia and Lymphoma Society
Universidad Autonoma de Madrid
Organization Involved with Phase 1 Indications (24)
Organization Involved with Other Experimental Indications (11)
Hierarchy Tree View
UMLS Data
YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.